SLC37A4 Antibody

What is SLC37A4 and why is it important in research?

SLC37A4 (Solute Carrier Family 37 Member 4) is a protein that functions as a glucose-6-phosphate translocase. It transports glucose-6-phosphate from the cytoplasm to the endoplasmic reticulum, where it works with glucose-6-phosphatase to break down glucose-6-phosphate into glucose and inorganic phosphate. This process is central to homeostatic regulation of blood glucose levels. SLC37A4 is particularly important in research related to glycogen storage diseases, particularly type Ib (GSDIb), which is caused by mutations in the SLC37A4 gene . Research using SLC37A4 antibodies helps elucidate the molecular mechanisms of glucose homeostasis, endoplasmic reticulum function, and metabolic disorders.

What applications are SLC37A4 antibodies typically used for?

SLC37A4 antibodies are commonly used in several experimental applications:

The optimal dilutions should be determined by the researcher for each specific experimental system and antibody source .

What tissue expression patterns should I expect when using SLC37A4 antibodies?

SLC37A4 is predominantly expressed in liver and kidney tissues, which is consistent with its role in glucose homeostasis. When using SLC37A4 antibodies for tissue staining, expect stronger signals in these gluconeogenic organs. Positive Western blot detection has been confirmed in HepG2 cells, HeLa cells, mouse kidney tissue, mouse liver tissue, and rat liver tissue . For immunohistochemistry, positive detection has been observed in human kidney and liver tissues. This tissue-specific expression pattern should be considered when designing experiments and interpreting results, particularly when studying tissue-specific aspects of glucose metabolism or glycogen storage disorders .

How should I optimize antibody dilutions for SLC37A4 detection in different applications?

Optimization of SLC37A4 antibody dilution requires systematic titration:

Western Blot Optimization:

• Begin with the manufacturer's recommended range (typically 1:500-1:2000)

• Perform a gradient dilution experiment using positive control samples (e.g., liver or kidney tissue lysates)

• Evaluate signal-to-noise ratio at each dilution

• Select the dilution that provides clear detection of the 46 kDa band with minimal background

IHC Optimization:

• Start with a median dilution (e.g., 1:100 for a range of 1:20-1:200)

• Test on known positive tissues (liver and kidney sections)

• Compare antigen retrieval methods - both TE buffer (pH 9.0) and citrate buffer (pH 6.0) have been reported effective

• Assess specific staining versus background at different dilutions

• Confirm specificity using negative controls (isotype controls and tissues not expressing SLC37A4)

Always include both positive and negative controls in optimization experiments to ensure reliable results .

What control samples are most appropriate for validating SLC37A4 antibody specificity?

For rigorous validation of SLC37A4 antibody specificity, include the following controls:

Positive Controls:

• Human, mouse, or rat liver tissue (high endogenous expression)

• Human, mouse, or rat kidney tissue (high endogenous expression)

• HepG2 cell lysates (human hepatocellular carcinoma cell line)

• HeLa cells (albeit with lower expression levels)

Negative Controls:

• Cell lines with CRISPR knockout of SLC37A4 (gold standard)

• Primary antibody omission control

• Isotype control (e.g., rabbit IgG at equivalent concentration)

• Tissues known to have minimal SLC37A4 expression

• Peptide competition assay using the immunizing peptide

For advanced validation, consider using CRISPR base-edited hepatoma cell lines harboring specific SLC37A4 mutations, which can provide valuable insights into antibody epitope specificity .

Why might I observe multiple bands in Western blot when using SLC37A4 antibodies?

Multiple bands in Western blot when using SLC37A4 antibodies may occur for several reasons:

• Post-translational modifications: SLC37A4 undergoes glycosylation which can result in heterogeneous migration patterns.

• Protein degradation: Partial proteolysis during sample preparation may generate fragments of SLC37A4 that are still recognized by the antibody. Ensure samples are prepared with fresh protease inhibitors and kept cold throughout processing.

• Splice variants: Though the canonical form of SLC37A4 is expected at 46 kDa, alternative splicing can generate variants with different molecular weights.

• Cross-reactivity: The antibody may recognize epitopes present in other proteins, particularly other members of the SLC37 family. Check if the observed bands correspond to known related proteins.

• Non-specific binding: High antibody concentrations can increase background and non-specific binding. Try more stringent washing steps and reduce primary antibody concentration.

To address this issue, perform peptide competition assays to identify which bands are specific, and consider using cell lines with confirmed SLC37A4 expression versus knockout lines as controls .

What are common fixation and antigen retrieval challenges with SLC37A4 antibodies in IHC?

SLC37A4 antibodies may present several challenges in immunohistochemistry related to fixation and antigen retrieval:

Common Challenges:

• Over-fixation: Excessive formalin fixation can mask epitopes. Limit fixation to 24-48 hours when possible.

• Antigen retrieval optimization: Since SLC37A4 is a transmembrane protein, epitope accessibility can be compromised. Both citrate buffer (pH 6.0) and TE buffer (pH 9.0) have been reported effective, but this is antibody-dependent. Comparative testing is recommended .

• Membrane protein accessibility: As a multi-transmembrane protein, some epitopes may be embedded in the lipid bilayer. Incorporation of mild detergents (0.1-0.3% Triton X-100) in washing buffers may improve epitope accessibility.

• Endogenous peroxidase activity: Particularly in liver tissue, endogenous peroxidase activity can create false positives. Thorough quenching with hydrogen peroxide (3% H₂O₂, 10 minutes) before antibody incubation is essential.

• Autofluorescence: Liver tissue exhibits significant autofluorescence. For IF applications, consider using Sudan Black B (0.1-0.3%) treatment post-antibody incubation to reduce autofluorescence, or spectral unmixing during imaging.

Testing different antigen retrieval methods and conditions is crucial for optimizing SLC37A4 detection in fixed tissues .

How can I distinguish between wild-type and mutant SLC37A4 proteins in patient samples?

Distinguishing between wild-type and mutant SLC37A4 proteins in patient samples requires specialized approaches:

• Epitope-specific antibodies: If available, use antibodies specifically raised against epitopes affected by common mutations. For example, antibodies targeting the C-terminal region would not detect truncated proteins from nonsense mutations like the recurrent c.1267C>T (p.Arg423*) variant .

• Immunoprecipitation followed by mass spectrometry: This can identify specific protein variants and post-translational modifications with high precision.

• CRISPR base-edited cell models: Generate cell lines carrying specific patient mutations (e.g., c.1267C>T) as reference controls. These can be particularly useful when studying dominant mutations causing congenital disorders of glycosylation .

• Subcellular fractionation and localization studies: Many pathogenic SLC37A4 variants cause protein mislocalization. Combine subcellular fractionation with Western blotting or immunofluorescence microscopy to assess whether the protein properly localizes to the endoplasmic reticulum or relocates to non-Golgi compartments, as observed with the p.Arg423* variant .

• Functional assays: Complement antibody detection with functional assays measuring glucose-6-phosphate transport activity to confirm the pathogenicity of variants.

This multi-faceted approach provides comprehensive characterization of mutant SLC37A4 proteins and their impact on cellular function .

What methodologies can assess SLC37A4 function alongside protein detection?

Integrating functional assessments with SLC37A4 protein detection provides more comprehensive insights into disease mechanisms:

• Microsomal transport assays: Isolate microsomes from cells or tissues and measure G6P uptake using radioisotope-labeled glucose-6-phosphate. This directly assesses SLC37A4 transport function.

• Glycogen quantification: Measure glycogen accumulation using periodic acid-Schiff (PAS) staining or biochemical assays in conjunction with SLC37A4 antibody staining to correlate protein levels with functional consequences.

• Golgi morphology assessment: As demonstrated in cells harboring the p.Arg423* variant, examine Golgi morphology and pH using appropriate markers (GM130, TGN46) and pH-sensitive dyes to identify changes associated with SLC37A4 dysfunction .

• N-glycosylation profiling: Analyze N-glycan profiles in serum or cell culture supernatants using mass spectrometry or lectin binding assays. Abnormalities in high mannose and hybrid type N-glycans can indicate SLC37A4 dysfunction, particularly in dominantly inherited disorders .

• Live-cell imaging: Use fluorescently tagged SLC37A4 constructs (wild-type and mutant) to track protein dynamics and localization in real-time, particularly in response to glucose fluctuations.

By combining protein detection with these functional approaches, researchers can better understand the consequences of SLC37A4 variants and potential therapeutic targets .

How do I reconcile contradictory findings when SLC37A4 antibody staining doesn't match known tissue expression patterns?

When faced with discrepancies between observed SLC37A4 antibody staining and expected tissue expression patterns, consider these methodological approaches:

• Verify antibody specificity: Conduct comprehensive validation using positive and negative controls, including tissues from SLC37A4 knockout models if available. Peptide competition assays can confirm binding specificity.

• Compare multiple antibodies: Different antibodies targeting distinct epitopes of SLC37A4 may give varied results. Use at least two antibodies recognizing different protein regions to cross-validate findings.

• Correlate protein with mRNA expression: Perform parallel in situ hybridization or RT-qPCR to assess SLC37A4 mRNA levels. Inconsistencies between mRNA and protein levels may suggest post-transcriptional regulation.

• Consider disease state influence: In pathological conditions, particularly glycogen storage diseases, expression patterns may differ from healthy tissues. Document sample pathology carefully.

• Evaluate detection sensitivity: Low expression levels may require signal amplification methods (e.g., tyramide signal amplification) for detection. Standard protocols might miss low abundance protein.

• Assess technical variables: Fixation methods, antigen retrieval conditions, and section thickness can all affect antibody penetration and epitope accessibility, especially for membrane proteins like SLC37A4.

Remember that SLC37A4 is predominantly expressed in liver and kidney tissues, so staining intensity should reflect this tissue-specific pattern under normal conditions .

What are the implications of altered SLC37A4 localization in disease models?

Altered subcellular localization of SLC37A4 in disease models has several important research implications:

• Functional consequences: SLC37A4 must localize to the endoplasmic reticulum membrane to form functional complexes with glucose-6-phosphatase enzymes. Mislocalization, such as that observed with the p.Arg423* mutant protein relocating to non-Golgi compartments, directly impacts glucose-6-phosphate transport and subsequent glucose production .

• Dominant negative effects: Some SLC37A4 mutations, particularly the recurrent c.1267C>T (p.Arg423*) variant, cause dominant inheritance patterns rather than the typical recessive inheritance of GSD1b. This may occur when mislocalized mutant protein interferes with wild-type protein trafficking or function .

• Secondary effects on cellular organelles: Research has demonstrated that SLC37A4 mutations can lead to gene dosage-dependent alterations in Golgi morphology and reduced intraluminal pH. These changes may explain broader cellular dysfunction, including abnormal protein glycosylation observed in patient samples .

• Therapeutic implications: Understanding the specific mislocalization pattern of mutant SLC37A4 proteins could inform targeted therapeutic approaches. For instance, compounds that promote proper protein folding or trafficking might be effective for mislocalization mutants but not for catalytically inactive variants.

• Biomarker potential: The pattern of SLC37A4 mislocalization, detected through subcellular fractionation or high-resolution microscopy with specific antibodies, may serve as a biomarker for specific disease subtypes or for monitoring therapeutic efficacy.

When interpreting localization data, correlation with functional assays is essential to establish the pathophysiological significance of observed changes .

How can SLC37A4 antibodies be used to investigate the interface between metabolism and immunity?

SLC37A4 antibodies offer valuable tools for investigating the unexplained connection between metabolism and immune function:

• Neutrophil dysfunction studies: GSD1b patients commonly exhibit neutropenia and neutrophil dysfunction through poorly understood mechanisms. SLC37A4 antibodies can be used in immunofluorescence co-localization studies with neutrophil markers to determine expression patterns in immune cells .

• Metabolic immunophenotyping: Combine SLC37A4 antibodies with flow cytometry to assess protein levels in different immune cell populations under various metabolic conditions. This can reveal how glucose-6-phosphate transport influences immune cell function and differentiation.

• Tissue microenvironment analysis: Multiplex immunohistochemistry using SLC37A4 antibodies alongside immune and metabolic markers can characterize the interplay between metabolic alterations and immune infiltration in diseased tissues.

• ER stress and inflammation crosstalk: Since SLC37A4 dysfunction can trigger ER stress, antibodies can be used to correlate protein expression with markers of the unfolded protein response (UPR) and inflammatory pathways in disease models.

• Glycosylation and immune recognition: SLC37A4 mutations can affect protein glycosylation, which is crucial for immune cell recognition. Antibodies can help track these alterations in glycoprotein processing and their impact on immune function.

This intersection represents an exciting frontier in SLC37A4 research, potentially explaining why patients with GSD1b develop neutropenia and other immune abnormalities .

What role might SLC37A4 play in cancer metabolism and how can antibodies help elucidate this?

The potential role of SLC37A4 in cancer metabolism can be investigated using specialized antibody applications:

• Expression profiling in tumor tissues: Systematic IHC analysis of SLC37A4 expression across tumor types and grades using tissue microarrays can identify cancers with altered expression. The Proteintech antibody (20612-1-AP) has been validated for this application in various human tissues .

• Metabolic adaptation mechanisms: Many cancers exhibit the Warburg effect (increased glycolysis despite oxygen availability). SLC37A4 antibodies can help determine if altered glucose-6-phosphate transport contributes to this metabolic reprogramming.

• Connection to circular RNAs: Recent research has identified links between circular RNAs like circ_0000235 and cancer progression through metabolic mechanisms. SLC37A4 antibodies have been used alongside other metabolic markers to investigate these pathways in bladder cancer .

• Hypoxia response studies: Combine SLC37A4 antibodies with hypoxia markers (HIF-1α) in dual immunofluorescence to examine how tumor hypoxia affects glucose-6-phosphate transport and metabolism.

• Therapeutic response biomarker: Monitor SLC37A4 expression before and after treatment with metabolic-targeting drugs to determine if changes in expression correlate with therapeutic response.

• Metastasis and invasion mechanisms: Investigate whether SLC37A4-dependent metabolic alterations contribute to increased migration and invasion capabilities in cancer cells, as suggested by knockdown studies of related metabolic pathways .

This emerging area of research may identify SLC37A4 as a potential therapeutic target or biomarker in cancers with dysregulated glucose metabolism .

What are the most promising future applications of SLC37A4 antibodies in translational research?

The future of SLC37A4 antibody applications in translational research holds significant promise in several areas:

• Precision medicine approaches: The development of mutation-specific antibodies could enable rapid identification of particular SLC37A4 variants in patient samples, facilitating personalized treatment approaches for different genetic subtypes of glycogen storage disorders.

• Biomarker development: SLC37A4 antibodies may serve as tools for developing minimally invasive biomarkers for monitoring disease progression and treatment response in GSD1b and related disorders, potentially reducing the need for invasive liver biopsies.

• Drug discovery platforms: High-content screening using SLC37A4 antibodies could identify compounds that restore proper localization or function of mutant proteins, particularly for dominant negative mutations like p.Arg423*.

• Gene therapy monitoring: As gene therapy approaches for GSD1b advance, antibodies will be crucial for assessing the expression, localization, and function of delivered transgenes in preclinical models and eventually in clinical samples.

• Organoid and iPSC disease modeling: SLC37A4 antibodies will be essential tools for validating patient-derived organoids and iPSC models, particularly for liver-specific manifestations of disease that require hepatic differentiation for accurate modeling.

These translational applications build upon the fundamental research capabilities of SLC37A4 antibodies and extend their utility into clinical research and therapeutic development .

What technological advances might improve SLC37A4 detection and functional analysis in the future?

Several technological advances are likely to enhance both detection sensitivity and functional analysis of SLC37A4:

• Single-molecule imaging: Super-resolution microscopy techniques (STORM, PALM) combined with specifically designed SLC37A4 antibodies will enable visualization of individual protein molecules and their dynamics within the ER membrane.

• Spatially-resolved proteomics: Emerging techniques like Digital Spatial Profiling or CODEX that combine antibody detection with spatial information will enable comprehensive mapping of SLC37A4 distribution and interactions within complex tissues.

• Nanobody development: The generation of SLC37A4-specific nanobodies (single-domain antibodies) may overcome limitations of conventional antibodies for live-cell imaging and intracellular immunoprecipitation applications.

• Quantitative assays: Development of highly sensitive ELISA or Luminex-based assays using well-validated antibodies will enable precise quantification of SLC37A4 in small biological samples, potentially including liquid biopsies.

• Functional antibodies: Engineering antibodies that not only detect SLC37A4 but can modulate its function (either enhancing or inhibiting) could provide valuable research tools and potential therapeutic leads.

• CRISPR-based reporters: Combining endogenous tagging of SLC37A4 through CRISPR knock-in approaches with specific antibodies will enable more physiologically relevant studies of protein dynamics and regulation.